1   *Special Report*

2   # A globally available COVID-19 – Template for clinical imaging studies

3

4   Salg, G.A.[1,2*], Ganten, M.K.[2*], Baumhauer, M.[2], Heußel, C.P.[3,4,5], Kleesiek, J.[6*]

5

6   [1] New Technologies and Data Science, Dept. General-, Visceral-, Transplantation Surgery, Heidelberg University
7   Hospital, Germany
8   [2] Mint Medical GmbH, Heidelberg, Germany
9   [3] Dept. Diagnostic and Interventional Radiology, Heidelberg University Hospital
10   [4] Dept. of Diagnostic and Interventional Radiology with Nuclear Medicine, Thorax Clinic at Heidelberg
11   University Hospital, Germany
12   [5] Translational Lung Research Center, Member of the German Center for Lung Research, Heidelberg, Germany
13   [6] Computational Radiology, Department of Radiology, German Cancer Research Center (DKFZ)

14

15   [*]G.A.S. and M.K.G. contributed equally

16

17   Corresponding author:
18   Dr. Dr. Jens Kleesiek, j.kleesiek@dkfz-heidelberg.de, German Cancer Research Center (DKFZ)

19

Highlights

- Dynamic evidence-based electronic case report form (eCRF) for COVID-19 including documentation of primary imaging data, secondary clinical data and patient history including radiomics features

- Computer-assisted, context-guided reporting approach based on FDA approved medical product software package available free of charge

- Data quality, traceability, integrity in open-access web platform

- Customizable analytics dashboard for explorative real-time data analysis of imaging features and clinical information

- Human and machine-readable data export for clinical trials

Abstract

Background

The pandemic spread of COVID-19 has caused worldwide implications on societies and economies. Chest computed tomography (CT) has been found to support both, current diagnostic and disease monitoring. A joint approach to collect, analyze and share clinical and imaging information about COVID-19 in the highest quality possible is urgently needed.

Methods

An evidence-based reporting template was developed for assessing COVID-19 pneumonia using an FDA-approved medical software. The annotation of qualitative and quantitative findings including radiomics features is performed directly on primary imaging data. For data collection, secondary information from the patient history and clinical data such as symptoms and comorbidities are queried.

Results

License-royalty free, cloud-based web platform and on-premise deployments are offered. Hospitals can upload, assess, report and if pseudonymized share their COVID-19 cases. The aggregation of radiomics in correlation with rt-PCR, patient history, clinical and radiological findings, systematically documented in a single database, will lead to optimized diagnosis, risk stratification and response evaluation. A customizable analytics dashboard allows the explorative real-time data analysis of imaging features and clinical information.

Conclusions

The COVID-19-Template is based on a systematic, computer-assisted and context-guided approach to collect, analyze and share data. Epidemiological and clinical studies for therapies and vaccine candidates can be implemented in compliance with high data quality, integrity and traceability.

An additional explanation video of the COVID-19-Template video is provided via:

http://cloud1.mint-

medical.de/downloads/player/index.html?v=Covid19StandardizedAssessmentWeb

Introduction

The infection with SARS-CoV-2 has become pandemic since the first cases have been reported from the Hubei province to the WHO on Dec. 31st, 2019. This led to a global health crisis with impacts for each individual patient infected with COVID-19, societies and economies.

Dynamic movement patterns, high contagiousness in combination with an estimated substantial asymptomatic and undocumented proportion of infected people[1] enables a fast spread of the infection and might only be slowed down by drastic disease containment efforts while vaccination and therapy are lacking.[2-4] The current situation in Italy and other parts of Europe proves that the previous measures for disease control did not suffice and that even countries with a strong health care infrastructure are not adequately staffed with critical care resources. Its current spread in low income countries or those with weak healthcare systems is to be feared.

Besides more aggressive containment, more efforts towards an evidence-based clinical diagnosis, treatment and monitoring including the utilization of new technologies and artificial intelligence are to be strived for.[5] The global spread of COVID-19 demands a global response across national borders. We perceive an urgent need for systematic data collection, comprising imaging data and analysis, of patients suffering from COVID-19 pneumonia. Therefore, we wish to initiate an open-access platform for data collection using commonly developed criteria for multi-modal diagnostics, staging and monitoring of the disease. This will serve as a mandatory foundation for swiftly conducting future clinical trials aiming at investigating novel diagnostic and therapeutic options.

Current evidence based on first studies

At present, real-time polymerase chain reaction (rt-PCR) is commonly used for diagnosis of COVID-19. This method, however, requires sophisticated lab technology and material with limited availability. Until now, the results are available earliest the next day. Meanwhile, the patient has to be treated as potentially COVID-19 positive, requiring costly isolation for safety of staff and eventually cohort isolation with a risk to get infected therein. While this method detects the virus, it does not provide quantitative data on the extent or stage of the disease. Fang et al. claimed that the sensitivity of rt-PCR at +3/-3 days after the appearance of external symptoms is only 71%.[6] The study also found that in 98% of patients at the same stage, abnormalities that are characteristic of viral pneumonia are visible in computed tomography (CT) of the lungs.[6] The correlation of COVID-19 infection with features in chest CT has been confirmed by other studies.[7] A sensitivity of 91.9% for a combination of a chest CT and rt-PCR test, compared to 78.2% for a single rt-PCR alone or 86.2% for two subsequent rt-PCR tests was found.[7] Researchers from China and the Netherlands examined data from 1,014 patients and concluded that CT imaging has high sensitivity for diagnosis of COVID-19 and furthermore offers the capability of screening, comprehensive evaluation, and follow-up.[8] Based on the chest CT imaging findings it can be concluded that there are correlations between the stage of the disease and the radiological appearance.[9] The imaging patterns visualized on CT offer the possibility to predict patient progression and the development of potential complications.[9] Guan et al. demonstrated that 18% of the total patients, who received an initial chest CT (n=877) had no radiological abnormalities (157/877) while only 3% (5/173) of the patients with severe disease course had no radiological abnormalities.[10] Although there might be a selection bias in many studies, rational usage of chest CT is a powerful tool in clinical monitoring of COVID-19. Moreover, timely underpinning of contagiosity for hospitalized patients via chest CT is crucial to prevent nosocomial infections and exposing medical staff at risk and thus additionally reducing human resources in hospitals. As the severe form of COVID-19 seems to show preference for middle-aged to elderly individuals with comorbidities,[11] the imaging information could be combined with other patient characteristics to predict the prognosis of patients, so as to identify those requiring intensive medical care.[12,13] Early stages of COVID-19 pneumonias mainly involve pure GGOs evolving to multiple GGOs with consolidations in lesions and crazy-paving pattern in a progressive stage.[14,15] This disease monitoring by chest CT imaging has already been used in studies to determine treatment regimens of patients.[11] We conjecture that the aggregation of radiomics features in correlation with rt-PCR, patient history, clinical and radiological findings, systematically

98 documented in a single database, will lead to optimized application of available resources in terms of
99 diagnosis, risk stratification and response evaluation of COVID-19.


Figure 1: Evidence-based template generation. Pooled patient data from the reviewed literature regarding comorbidities, clinical symptoms and radiological findings of COVID-19 positive patients. The blue circles represent the total number of patients of which the parameter was analyzed. The inner orange circle represents the number of patients that fulfilled the respective parameter.

100

101 The parameters for systematic data collection were determined based on the current evidence [last
102 update: 03-17-2020] and recommendations from several international medical associations. Findings
103 in the categories patient history and exposure, comorbidities, clinical symptoms, clinical chemistry and
104 radiological findings that might contribute to diagnosis or monitoring of COVID-19 or might be of
105 prognostic value for the course of the disease are included in the developed electronic case report
106 form (eCRF). As comorbidities have been described as a variable with prognostic value, study data for
107 comorbidities such as hypertension[10-13,16-18], cardiovascular diseases[10-13,16,17,19,20], chronic obstructive
108 lung disease and other respiratory system diseases[10-13,16,17,19,20], diabetes[10-13,16-18,20] and malignant
109 diseases[10-13,17,19,20] have been pooled (Figure 1, left). Clinical symptoms include fever,[10-13,15-21] cough,[10-
110 13,15-21] expectorations,[10-13,15-19,21] hemoptysis,[10,11,16,18] dyspnea,[10-13,15,16,19-21] headache[10-13,15-21] and
111 diarrhea[10-13,15-20] (Figure 1, middle). Radiological findings in chest CT performed on patients with
112 confirmed COVID-19 show radiological abnormalities in the majority of the cases (86.7%,
113 1122/1294),[10,16,17,19] typically with bilateral lung involvement,[10,11,17,18] peripheral distribution[16,17,19,21]
114 and ground-glass opacification of the lesions [10,16-19,21]. Depending on the stage of the disease
115 consolidations[16-19,21], intra-[18,21] and interlobular[16-18,21] septal thickening, crazy paving pattern,[16-18]
116 spider web signs[16,18] and air bronchogram sign[17,19,21] were observed (Figure 1, right). In contrast, pleural
117 effusion[16-19,21] and lymphadenopathy[16-19,21] were found rarely and do not seem to be typical for COVID-
118 19 pneumonia. Although current evidence for COVID-19 pneumonia relies on data from preliminary
119 clinical studies and thus is most likely subjected to change over time, we illustrated that some clinical
120 symptoms and radiological findings were found more frequently than others, supporting a diagnosis
121 of COVID-19 pneumonia, whereas others seem to be very rare and support a consideration of other
122 differential diagnoses (Figure 1). Nevertheless, or precisely because of it, these parameters were
123 included in the eCRF to enable a solid decision-making.

An approach for unified data collection and analysis using comparable criteria

125 Our proposal emphasizes the importance of quality, integrity and traceability of data to allow for later
126 epidemiological analysis and application of artificial intelligence algorithms. We wish to establish an
127 optimized digital signature of the disease consisting of imaging biomarkers, patient history and other
128 clinical follow-up data obtained in a reproducible matter. We demonstrate, that such a standardized
129 diagnostic procedure can be easily and globally implemented. The proposed template or eCRF,
130 respectively does not only provide a structured method for evaluating the pulmonary involvement but

131 is also essential for quantitative assessment of the progression of the disease in clinical trials beginning
132 in the near future. A standardized assessment is only possible if the imaging findings are quantitatively
133 collected and evaluated on a supra-regional, preferably global level using comparable criteria. A
134 representative assessment of COVID-19 pneumonia will be enabled by using the collected annotated
135 data consisting of primary imaging data and secondary clinical data. These provide structured primary
136 data that can be universally shared and analyzed. Therefore, an electronic case report form was
137 developed on the basis of the mint lesion™ medical software product platform (Mint Medical GmbH,
138 Heidelberg, Germany) (*Figure 2, 3*).

139 The template is available free of charge and has already been deployed to university hospitals and
140 health care providers in 8 countries around the world, including severely affected regions of the United


Figure 2: System. architecture cloud-based web platform. Every health care center has the possibility upload anonymized data to the web platform and use the eCRF based on the mint lesion medical product software package.


Figure 3: COVID-19 electronic case report form on mint lesion™ software platform. *Here:* Exemplary patient with confirmed COVID-19 pneumonia and chest CT at two subsequent time points. The patient was assessed and evaluated using the eCRF by an experienced radiologist. The assessment and evaluation are performed directly on primary imaging data and automatic rule-based evaluation of the disease progression. The patient was included in a clinical trial directly without the necessity of further data collection or twofold data documentation.

141 States and Italy as well as the majority of the university hospitals in Germany. In addition, a cloud-
142 based web platform will be provided, where every other hospital and health care center may have free
143 access and can upload, assess, report and document their cases (Figure 2, full exemplary report s.
144 supplementary information). Every center may choose and is encouraged to upload their
145 pseudonymized data in order to contribute to an open-access repository. An online dashboard of the
146 software will perform an explorative data analysis in real-time to monitor and alert if applicable. In
147 addition, a customized data analysis dashboard can be created by every user. All pseudonymized data
148 records submitted to the cloud are open-access and may be used to enhance the knowledge of COVID-
149 19 pneumonia and contribute to improved clinical care of COVID-19 patients in the near future.

150 **Electronic case report form (eCRF)**
151 The eCRF enables data acquisition in different levels. In detail, on an eCRF document level information
152 about the patient such as demographic information and exposure history but also about already
153 performed diagnostic measures and their respective results are requested to be recorded by the user.
154 In addition, secondary clinical data such as possibly relevant comorbidities, clinical symptoms and
155 clinical chemistry are queried. The selection of parameters is based on current study evidence as
156 described above. A dynamic flow of refinements and amendments is possible without the risk of
157 diminishing the quality of previously collected data. Furthermore, most recent results in evidence-
158 based markers can dynamically be integrated in the template. The assessment of the imaging part
159 includes general pulmonary radiological findings such as pleural effusion or lymphadenopathy.
160 Pulmonary findings that have been found to be compatible or in combination with other findings even
161 indicative for COVID-19 are automatically documented in a separate category depending on the
162 following described image findings. The eCRF allows for the documentation and measurement of
163 specific findings or general longitudinal monitoring on primary data. Methodological consistency and
164 conformity of the measurements are facilitated by the software architecture. Additional automatically
165 computed radiomics features will provide secondary data derived from the image. The measurement
166 of parenchymal abnormalities and the documentation of the grade of the lesion (e.g. ground-glass
167 opacification) at each time point (in case of several examinations) is annotated to the lobular


Figure 4: Overview of locations of major findings in chest CT. Longitudinal overview of documented findings
in chest CT examination (*here:* evaluation after second chest CT in COVID-19 disease course). Recession of
the size (LA: long axis, SA: short axis) of the imaging findings. These findings are included in an automatically
generated case report file for COVID-19 positive patient and study data repository.

168 sublocation in the lung. In accordance with the evidence described above, peripheral distribution
169 pattern of the lesions, bilateral lung involvement and other qualitative specifications of the lesions
170 with regards to their sublocation are evaluated automatically with a rule-based template framework.
171 This leads to an intelligent and simplified workflow supported by the logical constraints. A report for
172 each time point and for the longitudinal observation of the patient is generated automatically and
173 might be used for internal communication between departments (exemplary excerpt Figure 4; for full
174 report s. supplementary information).
175 The particular strength of the developed eCRF lies in the fact that any imaging-based value is
176 immediately linked to its context, e.g. anatomical location, but also further related data of clinical
177 significance. Due to the integration in the mint lesion software platform minable data is obtained in a
178 semantic data model with a HIPAA-and FDA CFR Part 11-ready audit trail, immediately applicable for
179 Phase I-III clinical trials and other medical research. Furthermore, data is exportable in various human-

180 and machine-readable data formats for external analysis. All image annotations can be exchanged in
181 open formats, like NRRD, or as DICOM-compliant annotations (DICOM RT, DICOM Seg. Surface Obj.).
182 Interfacing with other information systems, such as hospital information systems to include clinical
183 data, is possible through standardized interfaces, including HL7, FHIR, and openEHR. These interfaces
184 can also be used to transfer the automated report to the locally used RIS/HIS or other destinations.

185 **Discussion and Conclusion**

186 The proposed solution supports the detection and standardized recording of clinical and radiological
187 disease features consistent with the course of COVID-19 infection as well as the relevant
188 epidemiological disease history. We envisage that this data-driven approach will be used in current
189 and future research into therapies and vaccine candidates for COVID-19 pneumonia as well as future
190 viruses pneumonias, fibrotic diffuse interstitial lung diseases or other diseases with complex
191 characteristic patterns, as the evaluation of clinical trials on novel therapies and development of risk
192 stratification markers can be performed using the provided eCRF template. In addition, future analysis
193 can be performed on current and ongoing data reported via this structured approach due to the
194 systematic and harmonized data collection. As of today, many of the published studies lack a sufficient
195 number of cases or presented only retrospective results with partially incomplete information due to
196 challenges in data acquisition. Thus, many studies conclude that there is a need for a broader and
197 larger study with systematic data acquisition in the immediate future[10,12]. However, these studies
198 provide first data eligible for inclusion in a systematic prospective study protocol. We created the eCRF
199 based on the data extracted from the current studies. As Radiologists become more familiar with
200 radiological findings in line with COVID-19 pneumonia, the proposed eCRF will help to contribute
201 substantially to diagnosis and treatment of COVID-19 infection and facilitate pooling of international
202 knowledge. The template together with its automatically generated reports and computer-assistance
203 might also serve as a learning platform for further education. The rapid, pandemic spread showed,
204 that an extensive preparation and adjustment of healthcare systems is crucial to be able to respond
205 appropriately and timely. We hope that the structured guidance through the radiological assessment
206 together with the pooled information gathered from other sites might contribute to flatten the
207 learning curve and thus improve clinical management of patients suffering from COVID-19 infection.
208 Furthermore, resource scarcity in relation to the number of cases has been widely experienced by
209 means of medical consumables and infrastructure but also a shortage of health care professionals. A
210 cloud-based web platform dislodges the need for physical proximity to the hospitals or restrictions of
211 quarantine measures of radiologists. Teleradiology services can be easily enabled based on the
212 proposed concept, thus leading to larger capacities for COVID-19 pneumonia and beyond.
213 Our approach has limitations. Data acquisition and handling of an eCRF is more time consuming than
214 a reading in clinical routine. Further, integral data acquisition of imaging and clinical parameters
215 requires an interdisciplinary input, which might not be available for every case. Currently, the template
216 is designed for CT imaging only, but providing an eCRF for Chest-X-rays can be realized easily and is the
217 scope for future work. Lastly, it might also appear controversial, that an increased research effort is
218 encouraged even though manpower is limited during the current pandemic. The primary goal is to
219 provide a tool for future clinical studies which are urgently needed.
220 We do not want to present a predefined global standard for the assessment and reporting for patients
221 with COVID-19 infection, instead the intention is to initiate an evidence-based approach to define a
222 joint global standard that can be adapted to the dynamic situations and discoveries yet to come. This
223 might also discover regional difference in the disease leading to a personalized patient management.
224 The eCRF can be adapted and refined according to evidence generated in ongoing and future clinical
225 trials but also through the crowd-intelligence approach itself. Any addition or changes in template
226 parameters will not put previously collected data in danger. Data integrity is permanently ensured,
227 and even retrospective acquisition of certain parameters will be possible if applicable.
228 Chest CT as a supporting tool for diagnosis and furthermore therapy monitoring has distinct benefits
229 such as short turnaround time of the CT, wide availability of the equipment and the possibility of
230 assessing the stage of the disease including response to therapeutic measures. However, it needs to
231 be emphasized that even though the reporting is conducted directly on the CT image data, the eCRF

232   can be used even if there is no imaging dataset available. Parameters regarding the patient history,
233   clinical symptoms and clinical chemistry might still be documented systematically and shared with
234   other ongoing activities like the leoss-project (https://leoss.net). Consequentially, the target group of
235   users are not only radiological departments but every other department, that contributes to the
236   diagnosis and treatment of COVID-19 patients. We aim to provide 'role-dependent' eCRF template
237   solutions that can be integrated into one structured data set in the near future. Access to the cloud-
238   based web platform and the open access data repository will be announced on https://mint-
239   medical.com and through channels of the respective professional associations.
240   With the presented systematic, computer-assisted and context-guided approach to capture data and
241   annotations based on an easy-to-use software free of charge, we wish to contribute to a joint global
242   response against the COVID-19 pandemic in a balancing act between research and clinical routine and
243   further to initiate a change of clinical study culture.

Conflict of interest

Acknowledgements

References

257   1.   Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination
258   of novel coronavirus (SARS-CoV2). Science 2020.
259   2.   Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19
260   screened among close contacts in Nanjing, China. Sci China Life Sci 2020.
261   3.   Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation
262   of cases and contacts. Lancet Glob Health 2020.
263   4.   Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and
264   pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J
265   Microbiol Immunol Infect 2020.
266   5.   Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet 2020.
267   6.   Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR.
268   Radiology 2020:200432.
269   7.   Guanmin Jiang XR, Yan Liu, Hongtao Chen, Wei Liu, Zhaowang Guo, Yaqin Zhang, Chaoqun
270   Chen, Jianhui Zhou, Qiang Xiao, Hong Shan. Application and optimization of RT-PCR in diagnosis of
271   SARS-CoV-2 infection. medRxiv 2020.
272   8.   Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease
273   2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020:200642.
274   9.   Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19):
275   Relationship to Duration of Infection. Radiology 2020:200463.
276   10.   Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl
277   J Med 2020.
278   11.   Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary
279   hospitals in Hubei Province. Chin Med J (Engl) 2020.

280   12.   Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
281   in Wuhan, China. Lancet 2020;395:497-506.
282   13.   Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
283   Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
284   14.   Wei J, Xu H, Xiong J, et al. 2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed
285   Tomography Findings. Korean J Radiol 2020.
286   15.   Dai WC, Zhang HW, Yu J, et al. CT Imaging and Differential Diagnosis of COVID-19. Can Assoc
287   Radiol J 2020:846537120913033.
288   16.   Wu J, Wu X, Zeng W, et al. Chest CT Findings in Patients with Corona Virus Disease 2019 and
289   its Relationship with Clinical Features. Invest Radiol 2020.
290   17.   Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus
291   SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020.
292   18.   Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected Coronavirus
293   Disease 2019 in two emergency departments outside of Hubei, China. J Med Virol 2020.
294   19.   Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019
295   novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect
296   2020.
297   20.   Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019
298   novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
299   21.   Xu YH, Dong JH, An WM, et al. Clinical and computed tomographic imaging features of novel
300   coronavirus pneumonia caused by SARS-CoV-2. J Infect 2020.
301